Antiretroviral therapy (ART) can effectively suppress human immunodeficiency virus type 1 (HIV-1) replication and limit the disease progression. However, ART is unable to eradicate the virus, and the requirement for lifelong treatment may have side effects and poses a risk of the development of resistance. New approaches to prevent and treat HIV-1 infection should therefore be developed. HIV-1 capsid (CA) protein is an unexploited but attractive target for antiviral drug development. The hydrophobic cavity of C-terminal domain of CA (CA CTD) has been validated as a potential target for antiviral drugs. Binding of compounds to this conserved nonpolar groove in CA CTD allosterically disrupts the CA assembly. In the study described here, we screened 2,080 natural products to identify potential antiviral agents for further development to combat HIV-1 infection. From the primary screen at a fixed concentration of 50 µM, 16 compounds were found to be effective against this target. Then, 6 compounds observed in the primary screen were confirmed in dose-response experiments. Finally, the 6 selected compounds were tested against HIV-1-induced cytopathic effects. Two compounds showed inhibitory effect on HIV-1 replication, and the most active one, rubranol, inhibited viral replication at a moderate micromolar concentration (EC = 15.85 μM). The binding mode of rubranol and hirsutanonol to CA CTD were analyzed by molecular docking respectively, providing insight for design of drug targeting HIV-1 capsid. The research reports, for the first time, identification of natural products that showed potential as anti-HIV-1 agents by targeting conserved hydrophobic cavity of HIV-1 CA CTD.Copyright © 2020. Published by Elsevier B.V.
XB130, regulated by miR-203, miR-219, and miR-4782-3p, mediates the proliferation and metastasis of non-small-cell lung cancer cells.
March 12, 2020
August 12, 2015
D-Dimer level was associated with prognosis in metastatic colorectal cancer: A Chinese patients based cohort study.
February 13, 2020
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.